In 2014 Shah and colleagues showed that utilization of intravitreal anti-vascular endothelial growth factor (VEGF) after brachytherapy could weaken or delay the rate of moderate vision loss, macular edema, and poor visual acuity [57]. This evidence concerns the gene VEGFA and macular retinal edema.